CIA
CRSP icon

Concurrent Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Concurrent Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
+2,000
New +$105K ﹤0.01% 2019

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Concurrent Investment Advisors's CRSP Position: Q2 2026 in Review

Concurrent Investment Advisors increased its CRISPR Therapeutics (CRSP) stake by 45% in Q2 2026, buying an estimated $1.48M and bringing the position to 90,537 shares worth $4.94M. The position accounts for 0.04% of the portfolio, ranked #437.

Concurrent Investment Advisors first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Concurrent Investment Advisors held 90,537 shares of CRISPR Therapeutics worth $4.94M as of Q2 2026.
  • Concurrent Investment Advisors bought 28,114 CRISPR Therapeutics shares in Q2 2026, an estimated $1.48M.
  • CRISPR Therapeutics made up 0.04% of Concurrent Investment Advisors's portfolio in Q2 2026, its #437 holding.
  • Concurrent Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.